Recently,Medtronic DisclosureFinished2026Second Quarter Earnings Report of the Fiscal Year。Financial ReportDisplay,In pulsed field ablation (PFA) Technology-driven, the company's cardiac ablation solutions (CAS) Business Implementation71%Organic growth, in whichPFAProduct sales surged over300%, becoming the biggest highlight of this quarter's financial report.

Total Revenue of the Company This Quarter89.6Billion USD, year-on-year growth6.6%`, exceeding Wall Street expectations`88.6Billion USD; Adjusted Earnings Per Share1.36USD, higher than analysts' forecasts1.31Dollar.

Instrument News learned that this time MedtronicCardiac Ablation Solutions (CAS) Revenue surged year-over-year71%, including the growth in the U.S. market128%，mainly due toAffera PFASystem demand explodes. The system's installation volume doubled last quarter, with a significant increase in lab penetration, capturing the dominant share of atrial fibrillation procedures in most newly established labs.

PFASales soared over the same period last year300%, accounting for a significant proportion of the cardiac ablation business revenue.75%`, effectively hedging traditional cryoablation business`40%The downward pressure.Affera Sphere-9Dual-energy catheters gain clinical recognition for their advantages in shorter operation time and durability, while research productsSphere-360Single-needle catheter has been directed toFDASubmitIDEApplication, key trials to be launched soon.

Against the backdrop of intensifying global competition, MedtronicPFAFranchising Continues to Expand in the U.S. and International Markets, Says Medtronic Chairman and CEOGeoff MarthaEmphasizes that the current market share remains in the double-digit range, but a first-mover advantage has been established through technological iteration and the expansion of installed capacity.

"We delivered a strong performance in the second quarter,"Geoff Martha YesterdayExpressed during the earnings call with analysts："Our revenue and earnings per share both exceeded expectations. Across our entire business, procedure volumes and end markets were very strong, and we're leveraging the full capabilities of Medtronic to launch innovative technologies and execute ahead of the curve in some of the most attractive and fastest-growing end markets."

The following are some highlights from Medtronic's second quarter:

• Cardiovascular Segment Revenue34.4Billion USD (+10.8%), Diabetes Business7.57Billion US dollars (+10.3%), maintaining double-digit growth.

  
  

• Symplicity SpyralBenefits of Renal Denervation SystemCMSChina-wide coverage decision and expansion of commercial insurance coverage expected to drive revenue recovery in the second half of the year;AltavivaSurging Demand for Tibial Nerve Modulation Implants After Approval, Surgeon Training Programs Oversubscribed to Drive Case Accumulation.

  
  

• HugoRobotic Surgery System ReceivesFDAUrology Indications Approval Imminent, Poised to Open Up the U.S. Market。Chief Financial OfficerThierry PiétonIt is estimated that,WithHugoSoft Tissue Robotic Surgical System Enters the U.S. Market, Driving Better Growth in Both Internal and External Medical Businesses。He said:"In the second half of this fiscal year, we expectFDAWill ApproveHugo"And obtained the urology indication, we will begin to enter the U.S. market." "We are also continuously advancing the expansion of indications."

  
  

• The spin-off plan for the diabetes business is proceeding steadily, and the patch pump will be launched2026Submitted in the Fall of [Year]FDAApplication.

The company raises its full-year organic revenue growth guidance to5.5%, the adjusted earnings per share range is5.62-5.66USD.MarthaMedtronic emphasizes its shift to a "growth mindset," consolidating growth momentum by expanding manufacturing scale, increasing operational expenditure, and pursuing strategic acquisitions. The electrophysiology ablation market size exceeds120USD billion and annual growth20%, Medtronic believes that throughPFAThe expansion of technology implementation will reshape the competitive landscape of the industry.